NOT-NS-24-030: Notice of Correction to Expiration Date for PAR-24-063 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)"

Notice of Correction to Expiration Date for PAR-24-063 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)"

Notice Number:

NOT-NS-24-030

Key Dates

Release Date:

November 13, 2023

Related Announcements

November 1, 2023 - Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional). See NOFO PAR-24-063.

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this notice is to correct the expiration date for PAR-24-063 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)". The expiration date has been corrected to show this Notice of Funding Opportunity (NOFO) will expire on August 19, 2026. Changes to the NOFO are shown below.

Currently Reads:

Part 1. Overview Information

Key Dates:

Expiration Date: August 19, 2024

Modified to Read:

Part 1. Overview Information

Key Dates:

Expiration Date: August 19, 2026

All other aspects of this NOFO remain unchanged.

Inquiries

Please direct all inquiries to:

Charles Cywin, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email: [email protected]